also describe “type II LCNEC” which has a genetic resemblance to SCLC with TP53 and RB1 alterations, but with reduced activity of typical neuroendocrine markers and higher NOTCH pathway activation (43). This evidence concerns the gene TP53 and small cell lung carcinoma.